4 protocol(s) meet the specified criteria
PI: Riches, Marcie
Protocol No.TitleStatus
A051301 A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo In Patientswith Relapsed or Refractory Diffuse Large B-Cell Lymphoma Of The Activated B-Cell Subtype Open
CLFG316X2202A randomized, open label, controlled, multiple dose study to evaluate the clinical efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of LFG316 in patients with transplant associated microangiopathy after hematopoietic precursor cell transplantationOpen
EBV-CTL-201Multicenter Expanded Access Protocol of Allogeneic Epstein-Barr Virus Cytotoxic T Lymphocytes (EBV-CTLs) for Patients with EBV-Associated Lymphomas and Lymphoproliferative Disorders in Immunocompromised Patients for Whom There are No Other Comparable OptionsOpen
EBV-CTL-301Multicenter, Open-Label, Phase 3 Trial of Allogeneic Epstein-Barr Virus Cytotoxic T Lymphocytes (EBV-CTLs) for Allogeneic Hematopoietic Cell Transplant (alloHCT) Patients with EBV-Associated Post-Transplant Lymphoproliferative Disease (EBV-PTLD) after Failure of RituximabOpen